Close

Biocon Q4 net profit falls 54% to Rs 113 crore

Related stories

Cancer Diagnostics Market Outlook 2031: Growth Trends and Insights

The global cancer diagnostics market, valued at USD 163.7 billion...

Trends and Challenges to Face the Pharma Industry in 2024

The Clinical Research Organisation (CRO) sector is set for...

AAV Therapy Collaboration Amidst $2.57B CDMO Market Surge

The global market for cell and gene therapy biomanufacturing...

Syntegon with stable business development in 2022

Syntegon looks back on a stable business development in...

The Importance of Relationships in the Rare Disease Community

In my role as CRO Partner Manager, I’m responsible...

Biotechnology firm Biocon on Friday reported a 54.51 per cent fall in its consolidated net profit at Rs 113.08 crore for the fourth quarter ended March 31, 2014.
The company had posted a net profit of Rs 248.61 crore in the same period of the previous fiscal.

Net sales of the company rose to Rs 722.59 crore for the fourth quarter as against Rs 630.12 crore for the same period a year ago, Biocon Ltd said in a statement.
For the year ended March 31, 2014, the company’s net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-13 fiscal.
The company’s net sales for the just-concluded fiscal rose to Rs 2,852.72 crore, as against Rs 2,427.60 crore in the previous year.
In a separate statement, the Bangalore-based firm said it has appointed Arun Chandavarkar as the Chief Executive Officer and Joint Managing Director.
The company’s board also recommended a final dividend of Rs 5 per share (100 per cent) for the FY 2013-14.
Biocon shares were trading at Rs 481.10 apiece on the BSE, up 3.04 per cent from its previous close.

 

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories